德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06996 德琪医药-B

复活节星期一翌日休市 04-02 16:08:21

5.320

-0.040

-0.75%

最高5.460	最低5.220	成交量211.29万
今开5.410	昨收5.360	日振幅4.48%
总市值36.12亿	流通市值36.12亿	总股本6.79亿
成交额1,124万	换手率0.31%	流通股本6.79亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06996","market":"HK","secType":"STK","nameCN":"德琪医药-B","latestPrice":5.32,"timestamp":1775117301006,"preClose":5.36,"halted":0,"volume":2112926,"delay":0,"changeRate":-0.007462686567164185,"floatShares":679000000,"shares":679000000,"eps":-0.43314633247905454,"marketStatus":"复活节星期一翌日休市","change":-0.04,"latestTime":"04-02 16:08:21","open":5.41,"high":5.46,"low":5.22,"amount":11243188,"amplitude":0.044776,"askPrice":5.32,"askSize":8000,"bidPrice":5.3,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.44454492017587177,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":1605801600000,"exchange":"SEHK","adjPreClose":5.36,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":0.5087131432485261,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06996","defaultTab":"news","newsList":[{"id":"1178298832","title":"异动解读 | 德琪医药-B盘中大涨5.81%，执行董事增持及与优时比授权协议提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1178298832","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178298832?lang=zh_cn&edition=full","pubTime":"2026-03-26 10:16","pubTimestamp":1774491406,"startTime":"0","endTime":"0","summary":"德琪医药-B今日盘中股价大幅上涨5.81%，引起了市场的广泛关注。根据协议，德琪医药将获得8000万美元的首付款及近期里程碑付款，并有资格在未来获得最高约11亿美元的里程碑付款以及基于净销售额的分级特许权使用费。此外，分析报告指出，德琪医药作为一家专注于创新抗肿瘤药物的生物制药公司，其2025年度收入同比增长14.5%至1.05亿元人民币，亏损也显著收窄。内部增持与重大利好的授权协议共同作用，提振了市场对公司价值的认可和股价表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622020093","title":"执行董事龙振国增持德琪医药(06996)23.5万股 每股作价约4.14港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622020093","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622020093?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:14","pubTimestamp":1774437259,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，3月24日，执行董事龙振国增持德琪医药(06996)23.5万股，每股作价4.136港元，总金额约为97.2万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260325/20260325191438_18992.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260325/20260325191438_18992.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"执行董事龙振国增持德琪医药(06996)23.5万股 每股作价约4.14港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06996","BK1583","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622804144","title":"【券商聚焦】交银国际维持德琪医药(06996)买入评级  指其2026年有望盈亏平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=2622804144","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622804144?lang=zh_cn&edition=full","pubTime":"2026-03-25 13:13","pubTimestamp":1774415596,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，德琪医药 2025年收入同比+15%至1.05亿元，亏损收窄至2.39亿元。展望2026年，与优时比达成的ATG-201交易有望贡献8,000万美元近期付款，公司预计将显著增厚业绩并实现盈亏平衡，研发投入将有所回升。综合考虑2025全年业绩和ATG-201交易对未来业绩的增厚作用，该机构上调公司2026-27年收入及盈利预测，上调DCF目标价至10港元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977194","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169378976","title":"异动解读 | 德琪医药-B盘中大涨5.23%，业绩改善及管理层增持提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1169378976","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169378976?lang=zh_cn&edition=full","pubTime":"2026-03-25 09:50","pubTimestamp":1774403456,"startTime":"0","endTime":"0","summary":"德琪医药-B今日盘中大涨5.23%，引起了市场的广泛关注。消息面上，公司近期公布了2025年年度业绩，显示营收同比增长14.56%至1.05亿元，经调整后年内亏损同比收窄33.7%至2.02亿元，同时公司现金储备充足，核心临床管线取得积极进展，管理层预计今年会陆续达成更多合作。此外，公司创始人、首席执行官兼董事长梅建明博士，执行董事兼首席财务官龙振国先生，以及企业副总裁兼董事会秘书曹洋先生于近期在公开市场合计增持了公司股份，总代价约为385.3万港元。此举被市场解读为管理层对公司长期投资价值及未来发展前景抱有坚定信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622126670","title":"德琪医药-B(06996)获创始人、首席执行官、董事长及其他管理层增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2622126670","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622126670?lang=zh_cn&edition=full","pubTime":"2026-03-25 08:19","pubTimestamp":1774397993,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 发布公告，本公司董事会获本公司创始人、执行董事、首席执行官兼董事长梅建明博士告知，于2026年3月23日及24日，梅博士透过其控制的一间实体于公开市场以平均价格每股约0.512美元购入本公司合共20万股普通股，占已发行股份总数约0.029%。在遵守适用法律及监管规定的前提下，彼等不排除于适当时候进一步增持本公司股份的可能性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","BK1574","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622509942","title":"直击业绩会 | 德琪医药2025年亏损收窄，管理层称预计今年会陆续达成更多合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2622509942","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622509942?lang=zh_cn&edition=full","pubTime":"2026-03-24 23:49","pubTimestamp":1774367382,"startTime":"0","endTime":"0","summary":"3月20日，德琪医药（6996.HK）发布2025年年度业绩公告，并于3月23日召开业绩说明会，披露了全年经营数据及核心管线、技术平台的最新进展。财务数据显示，德琪医药2025年实现营业收入1.05亿元，同比增长14.56%，经调整后年内亏损（扣除汇兑差异净额）为2.02亿元，上年同期亏损为3.04亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682959074.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682959074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","06996","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165244984","title":"异动解读 | 德琪医药-B盘中大涨7.65%，2025年度业绩亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1165244984","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165244984?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:38","pubTimestamp":1774319924,"startTime":"0","endTime":"0","summary":"德琪医药-B（06996）今日盘中大涨7.65%，引起了市场的广泛关注。消息面上，公司发布了截至2025年12月31日止的年度业绩。报告显示，集团收入达到人民币1.05亿元，同比增长14.56%；研发开支为1.69亿元，同比减少34.69%；年内亏损为2.39亿元，同比减少25.10%；经调整年内亏损为2.33亿元，同比收窄23.50%。公告指出，收入增长主要得益于中国内地市场贡献加速，市场渗透率稳步提升以及商业化合作不断深化。这些积极的财务数据，尤其是亏损的大幅收窄，增强了投资者对公司未来盈利能力的信心，从而推动了股价的显著上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621034622","title":"港股异动 | 德琪医药-B(06996)盘中涨超3% 2025年度经调整年内亏损同比收窄23.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621034622","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621034622?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:33","pubTimestamp":1774319622,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B(06996)盘中涨超3%，截至发稿，涨3.57%，报4.06港元，成交额679.49万港元。消息面上，近日，德琪医药-B发布截至2025年12月31日止年度业绩，该集团取得收入人民币1.05亿元(单位下同)，同比增加14.56%；研发开支1.69亿元，同比减少34.69%；年内亏损2.39亿元，同比减少25.10%；经调整年内亏损2.33亿元，同比减少23.50%；每股亏损0.38元。公告称，收入增加主要是由于中国内地贡献加速所致，得益于市场渗透率稳步提升及商业化合作不断深化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06996","BK4585","BK1191","BK4588","BK1574","BK1583","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620786754","title":"德琪医药-B(06996)发布年度业绩 经调整年内亏损2.33亿元 同比减少23.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620786754","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620786754?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:35","pubTimestamp":1773995726,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布截至2025年12月31日止年度业绩，该集团取得收入人民币1.05亿元(单位下同)，同比增加14.56%;研发开支1.69亿元，同比减少34.69%;年内亏损2.39亿元，同比减少25.10%;经调整年内亏损2.33亿元，同比减少23.50%;每股亏损0.38元。公告称，收入增加主要是由于中国内地贡献加速所致，得益于市场渗透率稳步提升及商业化合作不断深化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06996","BK1574","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618935416","title":"每日卖空追踪 | 德琪医药-B 03月10日卖空量成交26.75万股，卖空比例为1.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618935416","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618935416?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:30","pubTimestamp":1773131438,"startTime":"0","endTime":"0","summary":"德琪医药-B北京时间03月10日，涨11.5%，卖空量成交26.75万股，较上一交易日减少48.11%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163550a45df9f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163550a45df9f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06996","BK1583","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618497935","title":"德琪医药-B盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618497935","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618497935?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:41","pubTimestamp":1773106901,"startTime":"0","endTime":"0","summary":"2026年03月10日早盘09时41分，德琪医药-B股票出现异动，股价快速上涨5.00%。截至发稿，该股报4.200港元/股，成交量55.05万股，换手率0.08%，振幅4.50%。资金方面，该股资金流入115.616万港元，流出105.306万港元。德琪医药-B股票所在的药品行业中，整体涨幅为0.65%。德琪医药-B公司简介：德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要在亚太地区开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310094141a45ceb35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310094141a45ceb35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1191","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618260871","title":"德琪医药-B(06996.HK)拟3月20日举行董事会会议批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618260871","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618260871?lang=zh_cn&edition=full","pubTime":"2026-03-10 07:07","pubTimestamp":1773097622,"startTime":"0","endTime":"0","summary":"格隆汇3月10日丨德琪医药-B(06996.HK)宣布，本公司将于2026年3月20日(星期五)举行董事会会议，藉以(其中包括)考虑并批准本公司及其附属公司截至2025年12月31日止年度业绩及其发布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260310/32055270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06996","BK1583","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618628681","title":"China International Capital Corporation Limited增持德琪医药(06996)62.7万股 每股作价约3.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628681","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618628681?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:53","pubTimestamp":1773053581,"startTime":"0","endTime":"0","summary":"据香港联交所最新数据显示，3月4日，China International Capital Corporation Limited增持德琪医药(06996)62.7万股，每股作价3.0616港元，总金额约为191.96万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260309/20260309185332_48275.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260309/20260309185332_48275.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","06996","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618117935","title":"近期交易合作|正大天晴小分子靶向药授权赛诺菲，德琪医药双抗授权优时比","url":"https://stock-news.laohu8.com/highlight/detail?id=2618117935","media":"药菓","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618117935?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:00","pubTimestamp":1773050411,"startTime":"0","endTime":"0","summary":"2026近期合作 & 交易事件01 睿跃生物被Gyre收购02 黑石押注梯瓦开发TL1A单抗03 正大天晴新药授权赛诺菲04 德琪医药CD3/CD19双抗授权给优时比05 施维雅25亿美元收购Day One01睿跃生物被Gyre收购2026年3月2日，美国Gyre Therapeutics宣布将以全股票交易方式收购睿跃生物，交易估值约3亿美元。03正大天晴新药授权赛诺菲3月4日，中国生物制药子公司正大天晴已与赛诺菲就JAK/ROCK抑制剂罗伐昔替尼在全球的开发、生产及商业化订立独家授权协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091807369545f3b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091807369545f3b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06996","BK1583","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617655039","title":"德琪医药-B获中金公司增持62.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617655039","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617655039?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:09","pubTimestamp":1772806198,"startTime":"0","endTime":"0","summary":"格隆汇3月6日丨根据联交所最新权益披露资料显示，2026年3月4日，德琪医药-B(06996.HK)获China International Capital Corporation Limited在场内以每股均价3.0616港元增持好仓62.7万股，涉资约192万港元。增持后，China International Capital Corporation Limited最新持好仓数目为4076.35万股，持好仓比例由5.90%上升至6.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306221011a6ab302a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306221011a6ab302a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1516","BK1564","LU0359202008.SGD","SG9999002828.SGD","06996","BK1574","BK1583","LU0359201612.USD","BK1501","BK1147","LU0359201885.HKD","LU1023057109.AUD","03908","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617387416","title":"每日卖空追踪 | 德琪医药-B 03月06日卖空量成交28.35万股，卖空比例为5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617387416","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617387416?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:30","pubTimestamp":1772785838,"startTime":"0","endTime":"0","summary":"德琪医药-B北京时间03月06日，涨1.3%，卖空量成交28.35万股，较上一交易日减少55.7%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306163559a6aa404e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306163559a6aa404e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06996","BK1574","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617638749","title":"一周医药速览（02.02-02.06）","url":"https://stock-news.laohu8.com/highlight/detail?id=2617638749","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617638749?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:45","pubTimestamp":1772783158,"startTime":"0","endTime":"0","summary":"京东健康：2025年净利润增长29.1%至53.75亿元，全年新药首发超100款近日，京东健康发布截至2025年12月31日止年度的年度业绩公告。截至2025年底，公司自营药房门店已超过300家。德琪医药将获得8000万美元的首付款及近期里程碑付款，其中包括6000万美元的首付款和满足若干条件后额外支付的2000万美元里程碑付款。公告显示，整体收入为5.49亿美元，较2024年下降13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306155002a4532b1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306155002a4532b1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06996","BK1574","BK1583","BK1161","BK1191","BK1515","09939","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617503918","title":"【券商聚焦】交银国际维持德琪医药(06996)买入评级 看好其差异化管线资产的潜在价值和BD出海机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2617503918","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617503918?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:03","pubTimestamp":1772759029,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，德琪医药-B 将授予优时比CD19/CD3双特异性T细胞连接抗体ATG-201的全球独家权益。根据协议条款，德琪医药将获得总计8,000万美元近期付款，包括6,000万美元首付款以及2,000万美元近期里程碑付款，并有望在未来获得最高超过11亿美元的里程碑付款及基于未来净销售额的分级特许权使用费。该机构看好公司CLDN18.2 ADC、TCE、口服CD73等差异化管线资产的潜在价值和BD出海机会。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126598197","title":"德琪医药-B（06996）2月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1126598197","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126598197?lang=zh_cn&edition=full","pubTime":"2026-03-05 12:26","pubTimestamp":1772684764,"startTime":"0","endTime":"0","summary":"德琪医药-B于2026年3月5日披露截至2026年2月28日止的股份变动月报表。本期内公司股本未发生任何增发、回购或注销，整体规模保持稳定。截至2026年2月底，公司法定股本为2,000,000,000股，面值每股0.0001美元，合计200,000美元，与上月持平；已发行普通股数量维持在679,244,132股，另有202,500股库存股份，总股本合计679,446,632股，报告期内无变动。公司同时确认已符合香港联交所对于上市公司公众持股比例的相关要求。本次公告由主席梅建明博士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617595428","title":"港股异动 | 德琪医药-B(06996)再涨超11% 与优时比达成近12亿美元授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2617595428","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617595428?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:31","pubTimestamp":1772677897,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B(06996)再涨超11%，该股昨日收涨近10%。截至发稿，涨11.71%，报3.53港元，成交额715.17万港元。消息面上，德琪医药日前与优时比宣布，双方已签署协议，德琪医药将授予优时比在全球范围内推进CD19/CD3双特异性T细胞连接抗体ATG-201的开发、生产及商业化的独家权益，并包括与ATG-201相关的生产技术授权。德琪医药将获得总计8000万美元（包括6000万美元首付款以及额外2000万美元近期里程碑付款），并有望在未来获得最高超过11亿美元的里程碑付款及基于未来净销售额的分级特许权使用费。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06996","BK1574","BK1191","BK1583","BK4588","VT","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.antengene.com","stockEarnings":[{"period":"1week","weight":0.1319},{"period":"1month","weight":0.8472},{"period":"3month","weight":0.3606},{"period":"6month","weight":-0.1927},{"period":"1year","weight":0.5114},{"period":"ytd","weight":0.4037}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要从事生物科技产品的发现、开发、生产及商业化。该公司的主要产品包括用于治疗复发╱难治性多发性骨髓瘤、复发╱难治性弥漫大B细胞淋巴瘤和非小细胞肺癌的ATG-010(selinexor)及用于治疗肝细胞癌和非小细胞肺癌等多种适应症的ATG-008(onatasertib)。该公司主要在亚太地区开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.088806},{"month":2,"riseRate":0.166667,"avgChangeRate":0.291534},{"month":3,"riseRate":0.5,"avgChangeRate":0.091928},{"month":4,"riseRate":0.5,"avgChangeRate":-0.024405},{"month":5,"riseRate":0.6,"avgChangeRate":0.040777},{"month":6,"riseRate":0.2,"avgChangeRate":-0.111296},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000904},{"month":8,"riseRate":0.4,"avgChangeRate":-0.030428},{"month":9,"riseRate":0.4,"avgChangeRate":-0.020432},{"month":10,"riseRate":0.4,"avgChangeRate":0.032822},{"month":11,"riseRate":0.6,"avgChangeRate":0.05603},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.002542}],"exchange":"SEHK","name":"德琪医药-B","nameEN":"ANTENGENE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"德琪医药-B,06996,德琪医药-B股票,德琪医药-B股票老虎,德琪医药-B股票老虎国际,德琪医药-B行情,德琪医药-B股票行情,德琪医药-B股价,德琪医药-B股市,德琪医药-B股票价格,德琪医药-B股票交易,德琪医药-B股票购买,德琪医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}